MedTrace Logo

A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

NCT06916793 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2025-04-08

No results posted yet for this study

Summary

This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia

Conditions

Interventions

DRUG

CKD-843 dose#1

IM injection every 3 months for 12 months

DRUG

CKD-843 dose#2

IM injection every 3 months for 12 months

DRUG

Placebo of CKD-843 dose

IM injection every 3 months for 12 months

DRUG

Dutasteride Capsules

oral, once daily, 12 months

DRUG

Placebo of Dutasteride Capsule

oral, once daily, 12 months

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • OhSang Kwon, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2026-12-19
Completion
2027-09-17

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06916793 on ClinicalTrials.gov